Femara (Letrozole) and Levothyroxine Interaction: What Women Using Both for Fertility Need to Know

What Is the Actual Interaction Between Letrozole and Levothyroxine?

The short answer is that letrozole and levothyroxine do not directly compete at the same enzyme or transporter. There is no CYP2A6 or P-glycoprotein clash between these two drugs. The interaction is physiologic, not pharmacokinetic. Uncontrolled or suboptimally controlled hypothyroidism reduces your chances of responding to letrozole because thyroid hormone is a core regulator of the hypothalamic-pituitary-ovarian (HPO) axis.

How Thyroid Hormone Affects Ovulation

Thyroid-stimulating hormone (TSH) receptors are present on granulosa cells in the ovarian follicle. When TSH is elevated (hypothyroid state), thyroid-releasing hormone (TRH) rises in parallel and stimulates prolactin release from the pituitary. Elevated prolactin suppresses GnRH pulsatility, blunting the LH surge you need for ovulation. Studies have shown that even subclinical hypothyroidism (TSH 2.5 to 10 mIU/L) is associated with anovulation and luteal phase defects, which means letrozole has a harder job if your thyroid is not well replaced.

How Letrozole Works (and Why Thyroid Status Matters)

Letrozole is a third-generation aromatase inhibitor. It blocks the conversion of androgens to estrogens in peripheral tissue, temporarily lowering circulating estradiol. The pituitary senses this drop and increases FSH output, driving follicular recruitment. The NEJM's landmark PPCOS II trial (n = 750 women with PCOS) confirmed letrozole as the superior first-line ovulation-induction agent over clomiphene, with a live-birth rate of 27.5% vs. 19.1%. That FSH-amplification mechanism depends on an intact HPO axis, and hypothyroidism is one of the clearest ways to blunt it.

The Absorption Angle: Indirect but Real

Levothyroxine has a narrow therapeutic window and notoriously variable oral bioavailability, ranging from 64 to 80% under ideal fasting conditions. Many women on ovulation-induction cycles also take prenatal vitamins, calcium, or iron supplements. These do not interact with letrozole, but they significantly reduce levothyroxine absorption when taken within two to four hours of the levothyroxine dose. If your TSH creeps up because of an absorption problem during a letrozole cycle, your ovulatory response suffers. The fix is consistent timing, not a drug change.

Who Is Most Likely to Be Taking Both Drugs

You are most likely managing both letrozole and levothyroxine if you fall into one of these overlapping groups.

Women With PCOS and Autoimmune Thyroid Disease

PCOS and Hashimoto thyroiditis co-occur at a striking rate. A 2018 meta-analysis in the journal Clinical Endocrinology found that thyroid autoimmunity affects 22.5% of women with PCOS, compared with roughly 8% in the general female population. Many of these women are on levothyroxine for Hashimoto-related hypothyroidism and on letrozole for PCOS-related anovulation. If that is your situation, thyroid optimization is not optional before starting an ovulation-induction cycle.

Women in Their Late Reproductive Years (Perimenopause Approaching)

Hypothyroidism prevalence rises with age. In women aged 35 to 44 who are still trying to conceive, both thyroid dysfunction and declining ovarian reserve are common. Letrozole is sometimes used in this group even when cycles are irregular but not fully anovulatory. The American Thyroid Association's 2017 guidelines on thyroid disease in pregnancy specify a TSH target of 2.5 mIU/L or lower in women who are trying to conceive, which is more stringent than the non-pregnant reference range upper limit of roughly 4.5 mIU/L.

Women With Unexplained Infertility

Before attributing infertility to unexplained causes, subclinical hypothyroidism should be ruled out. A TSH between 2.5 and 4.5 mIU/L sits within most laboratory reference ranges but may still impair implantation. A 2020 Cochrane review on interventions for unexplained subfertility highlighted thyroid evaluation as part of standard workup before any ovulation-induction protocol.

Pharmacology Deep Dive: CYP Enzymes, Transporters, and Protein Binding

This is the section most competitor articles skip. Here is the full pharmacokinetic picture so you can have an informed conversation with your prescriber.

Letrozole's Metabolic Pathway

Letrozole is metabolized primarily by CYP2A6 and CYP3A4 in the liver. It is moderately protein-bound (approximately 60%, largely to albumin). It does not induce or inhibit CYP enzymes at therapeutic doses used in fertility (2.5 to 7.5 mg for five days). Its half-life is approximately 45 hours in healthy adults, meaning drug levels are largely cleared before the next cycle begins.

Levothyroxine's Metabolic Pathway

Levothyroxine (T4) is transported into cells via organic anion transporting polypeptides (OATPs) and converted to the active triiodothyronine (T3) primarily by deiodinase type 1 in the liver and kidney. It is more than 99% protein-bound to thyroxine-binding globulin (TBG), albumin, and transthyretin. Neither CYP2A6 nor CYP3A4 is meaningfully involved in levothyroxine metabolism.

Why There Is No Direct DDI

Because the two drugs use completely separate metabolic pathways and transporters, co-administration does not change the plasma concentration of either drug through a pharmacokinetic mechanism. No dose adjustment of letrozole is required because you take levothyroxine, and vice versa. What matters is that levothyroxine is doing its job effectively so that your HPO axis is responsive.

Protein Binding: A Theoretical Consideration

Both drugs bind to albumin. In theory, two highly protein-bound drugs taken simultaneously could displace each other, raising free fractions. In practice, this is not clinically significant for letrozole (only 60% bound) combined with levothyroxine (>99% bound to TBG, not primarily albumin). No published case reports or pharmacokinetic studies document a clinically meaningful displacement interaction between these two agents.

Monitoring Protocol During a Combined Letrozole and Levothyroxine Cycle

Monitoring is where the real clinical work happens. Here is a practical, evidence-anchored protocol.

Before Starting Letrozole

• Check TSH, free T4, and thyroid peroxidase antibodies (TPO-Ab) if not done in the past three months.
• Target TSH below 2.5 mIU/L before initiating ovulation induction. The Endocrine Society's 2012 clinical practice guidelines for management of thyroid dysfunction during pregnancy and postpartum recommend this pre-conception TSH target.
• If TSH is above 2.5 mIU/L, discuss a levothyroxine dose increase with your prescriber and allow four to six weeks for TSH to restabilize before proceeding.
• Confirm you are taking levothyroxine on an empty stomach, at least 30 to 60 minutes before your first meal and at least four hours away from calcium, iron, or multivitamins.

During the Letrozole Cycle (Days 3 to 7)

• Letrozole itself does not alter levothyroxine levels.
• Continue your levothyroxine dose and timing unchanged.
• Monitor follicular development with transvaginal ultrasound around cycle days 10 to 12 per your clinic's protocol.
• If you are using trigger injection (hCG) to time ovulation, TSH should already be at goal before triggering.

After a Positive Pregnancy Test

This is the most critical monitoring window. Thyroid hormone requirements increase by roughly 30 to 50% in early pregnancy due to rising TBG levels, placental deiodinase activity, and fetal thyroid hormone demands. ACOG Practice Bulletin No. 223 on thyroid disease in pregnancy recommends checking TSH as soon as pregnancy is confirmed and every four weeks through mid-pregnancy in women on levothyroxine. Many endocrinologists advise women to proactively increase their levothyroxine dose by 25 mcg (roughly one additional dose two days per week) as soon as a pregnancy test is positive, then confirm with TSH.

Pregnancy, Lactation, and Contraception: Required Safety Section

This section is required for every drug article on WomanRx, and it is especially important here because letrozole carries a serious pregnancy contraindication while levothyroxine is one of the safest drugs in pregnancy.

Letrozole in Pregnancy

Letrozole is contraindicated in pregnancy. The FDA prescribing information for letrozole classifies it as a category D teratogen based on animal data showing embryo-fetal toxicity, skeletal malformations, and increased fetal loss. In the context of fertility treatment, letrozole is taken on cycle days 3 to 7, well before a pregnancy test would be positive. The drug's half-life of 45 hours means it is largely cleared from your system before implantation would occur. However, you must stop letrozole immediately if you suspect pregnancy, and you should not take a second cycle if you have not yet had a negative pregnancy test from the prior cycle.

Reassuringly, the large prospective PPCOS II trial and a subsequent meta-analysis of over 1,600 letrozole-exposed pregnancies found no increase in congenital malformations compared with natural conception, consistent with the drug's clearance before the embryonic period of organogenesis.

Levothyroxine in Pregnancy

Levothyroxine is safe and necessary in pregnancy. It has an established safety record across decades of use. The American Thyroid Association's 2017 pregnancy guidelines confirm that adequately treated hypothyroidism carries no increase in fetal risk. Untreated or undertreated hypothyroidism, by contrast, is associated with miscarriage, preterm birth, placental abruption, and neurocognitive deficits in offspring.

Lactation

Levothyroxine passes into breast milk in small amounts. These amounts are physiologic and considered safe for infants; the drug is not contraindicated during breastfeeding. The National Institutes of Health LactMed database confirms levothyroxine as compatible with breastfeeding.

Letrozole is not indicated postpartum or during lactation in the fertility context. Data on letrozole in human milk are absent, and because it is an antiestrogen, any exposure in a breastfeeding infant would be a theoretical concern. It should not be used while breastfeeding.

Contraception

Because letrozole is teratogenic in animal models, women who are prescribed it for any purpose other than fertility must use effective contraception. In the fertility context this is self-evidently not applicable, but if you are prescribed letrozole for another reason (e.g., endometriosis adjunct therapy or off-label use), discuss reliable contraception with your provider.

Who This Is Right For (and Who Should Pause)

Letrozole plus levothyroxine is a reasonable combination for the right candidate. It is not right for everyone.

Right for You If

• You have confirmed anovulatory or oligo-ovulatory infertility (classic PCOS presentation).
• Your TSH has been optimized to below 2.5 mIU/L on a stable levothyroxine dose for at least four to six weeks.
• You do not have another cause of infertility that letrozole cannot address (severe tubal factor, azoospermia in partner, premature ovarian insufficiency).
• You are in your reproductive years and not yet perimenopausal (FSH below 10 IU/L on cycle day 3).

Pause or Adjust If

• Your TSH is above 2.5 mIU/L. Starting a letrozole cycle on a suboptimal thyroid baseline means you may cycle without ovulating and count it as a letrozole failure when the real issue was thyroid under-replacement.
• You have overt hyperthyroidism (TSH suppressed below 0.1 mIU/L). Hyperthyroidism also disrupts the HPO axis and increases miscarriage risk; this must be treated before ovulation induction.
• You have positive TPO antibodies with a TSH above 2.5 mIU/L. A 2019 randomized trial in Human Reproduction (n = 600) found that levothyroxine treatment in euthyroid women with TPO antibodies did not improve live-birth rate in IVF, but the picture is less clear for ovulation induction with letrozole in women with subclinical hypothyroidism; your endocrinologist's input matters here.
• You are in perimenopause with an elevated FSH (above 15 to 20 IU/L). Ovarian reserve testing (AMH, antral follicle count) should guide whether letrozole is appropriate at all.

Practical Timing and Dosing Guide

Here is what a combined letrozole and levothyroxine schedule looks like in a real cycle.

Sample Cycle Day Schedule

| Cycle Day | Action | |---|---| | Day 1 (first day of flow) | Call clinic to confirm cycle start; continue levothyroxine as usual | | Day 2 | Baseline ultrasound and bloodwork (TSH, estradiol, FSH if indicated) | | Days 3 to 7 | Letrozole 2.5 to 7.5 mg once daily in the morning; take levothyroxine at least 30 min before letrozole or at a different time of day | | Day 10 to 12 | Follicle tracking ultrasound; LH surge monitoring or hCG trigger | | Day 14 (approx.) | Timed intercourse or IUI | | Day 28 (approx.) | Pregnancy test | | If positive | Increase levothyroxine by 25 mcg and check TSH within two weeks |

Should You Take Letrozole and Levothyroxine at the Same Time?

There is no pharmacokinetic reason you cannot. But because levothyroxine absorption is so finicky, the safest practice is to take levothyroxine first thing in the morning on an empty stomach and take letrozole at least 30 to 60 minutes later with or without food. This keeps the levothyroxine absorption window clean. Your prenatal vitamins go at a completely different time of day (lunch or dinner) to avoid iron and calcium interference with levothyroxine.

Dosing Ranges

• Letrozole for ovulation induction: 2.5 mg daily for five days is the starting dose per ASRM practice guidelines, with dose escalation to 5 mg or 7.5 mg in subsequent cycles if the first cycle is unsuccessful.
• Levothyroxine: individualized by weight and etiology. A commonly used starting estimate is 1.6 mcg/kg/day for full replacement in overt hypothyroidism. Dose adjustment during pregnancy is guided by serial TSH, not a fixed increment.

Femara Drug Interactions Beyond Levothyroxine

While levothyroxine does not directly interfere with letrozole, other drugs in a fertility patient's medicine cabinet can.

CYP2A6 Inhibitors

Drugs that inhibit CYP2A6 could theoretically slow letrozole clearance and raise drug exposure. Clinically meaningful CYP2A6 inhibitors include methoxsalen (used for psoriasis) and high-dose tranylcypromine (an MAOI). These are uncommon in the fertility population but worth flagging.

Tamoxifen

The letrozole FDA label warns that co-administration with tamoxifen reduces letrozole plasma levels by approximately 38%. In breast cancer adjuvant therapy, this is a documented DDI. In fertility practice, these two drugs are not typically combined, but it is worth knowing if you have a history of breast cancer and are considering letrozole for ovulation induction.

Estrogen-Containing Products

Oral contraceptive pills and estrogen patches counteract letrozole's mechanism of action. You should stop estrogen-containing contraceptives before starting a letrozole ovulation-induction cycle.

Common Supplements in Fertility Patients

• Iron and calcium supplements: reduce levothyroxine absorption, not letrozole.
• CoQ10, DHEA, inositol: no known pharmacokinetic interaction with either drug.
• Soy isoflavones at high doses: may theoretically affect thyroid hormone levels; keep soy supplement intake moderate.

Evidence Gaps: What We Do Not Know Yet

Women have been historically under-represented in pharmacokinetic drug interaction studies. Here is where the evidence is thin and where you deserve honesty rather than false confidence.

• No head-to-head randomized trials have specifically examined letrozole ovulation-induction success rates in women stratified by thyroid status and levothyroxine dose. The link between TSH optimization and letrozole response is biologically logical and supported by observational data, but a powered RCT does not yet exist.
• Most letrozole pharmacokinetic data comes from postmenopausal breast cancer patients, not reproductive-age women on ovulation induction. Drug metabolism may differ slightly across the menstrual cycle due to fluctuations in CYP enzyme activity, but this has not been formally studied for letrozole.
• The optimal TSH threshold specifically for letrozole cycles (as opposed to IVF or natural conception) has not been studied in an RCT. The 2.5 mIU/L target is extrapolated from general pre-conception guidance.

"The TSH target of 2.5 mIU/L before ovulation induction is a clinical convention based on pregnancy outcome data, not a threshold derived from letrozole-specific trials," explains Dr. Elena Vasquez, MD, reproductive endocrinologist and WomanRx editorial board reviewer. "Until we have that letrozole-specific evidence, optimizing thyroid function before any fertility cycle remains the standard of care, and erring on the lower end of normal TSH is reasonable."